For moderate to severe rheumatoid arthritis (RA) in adult TNFi‑IR patients1
With or Without MTX2-5
RINVOQ achieved DAS28-CRP<2.6* and DAS28-CRP≤3.2
(ranked secondary endpoints) at Week 12 or 14, with durable
remission and low disease activity rates out to ~5 years.1,2,4,6,7
*Does not mean drug-free remission or complete absence of disease activity.
RINVOQ is indicated for TNFi-IR patients.
CRP=C-reactive protein; DAS28-CRP=28 joint disease activity score using C-reactive protein;
IR=intolerance or inadequate response; MTX=methotrexate; TNFi=tumor necrosis factor inhibitor
*P<0.0001 RINVOQ vs Placebo
SELECT-BEYOND (STUDY RA-V):1,8
12-week, randomized, double-blind, placebo-controlled study of 499 adult patients with moderate to severe RA who had an inadequate response or intolerance to bDMARDs. Patients on background csDMARDs were randomized to receive RINVOQ 15 mg once daily (n=164) or placebo (n=169). The primary endpoint was ACR20 response at Week 12.
*P<0.0001 RINVOQ vs MTX
RINVOQ IS INDICATED FOR TNFi-IR PATIENTS.
SELECT‑MONOTHERAPY (Study RA-II) Study Design Intro:1,6
14‑week, randomized, double‑blind, active comparator‑controlled study of 648 adult patients with moderate to severe RA who had an inadequate response to MTX. The primary endpoint was ACR20 response at Week 14.